Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Why Esports Entertainment Group (GMBL) Shares Are Plunging

Esports Entertainment Group, Inc. (NASDAQ: GMBL) shares are trading lower by 26% to $0.0151 Wednesday morning after the company announced a 1-for-400 reverse stock split of its common stock.
byHenry Khederian
December 20, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Esports Entertainment Group, Inc. (NASDAQ:GMBL) shares are trading lower by 26% to $0.0151 Wednesday morning after the company announced a 1-for-400 reverse stock split of its common stock.

This move, effective December 21st, aims to comply with Nasdaq listing requirements by reducing outstanding shares from around 426 million to approximately 1.065 million. The reverse split won’t affect ownership percentages, but fractional shares will be rounded up.

This action will also proportionately reduce the authorized shares of common stock from 500 million to 1.25 million shares.

See Also: Why KULR Technology Group Shares Are Down 27%

According to data from Benzinga Pro, GMBL has a 52-week high of $23.80 and a 52-week low of $0.01.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

OmniLit Acquisition Corp. Signed A Letter Of Intent For A Business Combination With An Affiliate Company; The Target Is An Advanced Manufacturer Of Optics And Photonics Components And Sub-Systems

By Benzinga Newsdesk
December 19, 3:59 PM
OmniLit Acquisition Corp. (“OLIT”) a publicly traded optics and photonics focused special purpose acquisition company, signed a letter of intent for a business combination with an affiliate company (the “Target”) that seeks to become a publicly listed company with an estimated Enterprise Value in the range outlined in OLIT’s IPO prospectus.

OLIT

Read More

FDA Experts Weigh In On Incannex’s CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorder

By Jelena Martinovic
May 7, 12:35 PM
Incannex Healthcare Inc., a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-O for the treatment of opioid use disorder (OUD).A number of FDA representatives shared insights on the CannQuit-O development program during the pre-IND teleconference in addition to providing recommendations on the proposed clinical development strategy.

IXHL